Eli Lilly and Company announced yesterday that the European Medicines Agency (EMEA) has granted enzastaurin, an investigational, multi-targeted, oral, cancer agent, orphan drug designation for the treatment of diffuse large B-cell lymphoma (DLBCL). Although rare, DLBCL is the most common sub-type of non-Hodgkin's lymphoma (NHL) of which approximately 50% of high-risk patients (high-risk is defined as having an International Prognostic Index score of 3-5) relapse within three years after receiving first line therapy.
Orphan medicinal products are for diagnosing, preventing or treating life- threatening or very serious conditions that are rare and affect not more than 5 in 10,000 persons in the European Union.
No comments:
Post a Comment